The Arora Report

Rss Facebook Twitter Linkedin

Stock Market News To Give You An Edge

Proven Track Record of Most Accurate Analysis

Stock Market News
To Give You An Edge​

Proven Track Record
of Most Accurate Analysis

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

A SPECIAL NOTE FOR NEW SUBSCRIBERS, LONG-TERM INVESTMENTS AND/OR SHORT-TERM TRADES, AN IMPORTANT TIP $FLXN $XBI $IBB $LABU $LABD $SPY

March 23, 2017

This post was just published on ZYX Buy Change Alert.  Our subscribers have a wide range of interests. Some focus only on long-term investments, others focus only on short-term trades.  Some do both. If your focus is on long-term investments, there is no need to be nimble.  There is no need to be watching your computer screen.  We typically give buy zones ahead of time.  Usually there is plenty of time to act at your convenience. If you are a long-term investor, you can simply ignore emails related to short-term trades and emails titled INTELLIGENCE.  Please read tip number 10 under Important

Read More »

PLAN ON FLEXION THERAPEUTICS, QUICK DENIAL MAY MEAN HIGHER POTENTIAL OF A BUYOUT $FLXN $SNY

March 23, 2017

This post was just published on ZYX Buy Change Alert. A quick denial of a potential deal is not typical, as has happened in the case of FLXN.  One hypothetical explanation is that  the deal is potentially in the works but a quick run-up in the stock makes the deal difficult.  Hypothetically, this could be the reason for a quick denial. Fortunately we were able to be nimble. Subscribers who were able to be nimble made some profits.  Subscribers who were not able to be nimble, did not lose any money. The Plan If the historical pattern holds, the stock is likely

Read More »

TAKE PROFITS ON FLEXION THERAPEUTICS RIGHT HERE AROUND $25.88, IF FILLED $FLXN $SYN

March 23, 2017

This post was just published on ZYX Buy Change Alert.   You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES. Please click here to take advantage of a FREE  30 day trial. Check out our enviable performance in both bull and bear markets.

Read More »

FLEXION THERAPEUTICS: CHANGING THE BUY ZONE TO $20 TO $21.15, SNY DENIES THE DEAL $FLXN $SYN

March 23, 2017

This post was just published on ZYX Buy Change Alert. More later You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES. Please click here to take advantage of a FREE  30 day trial. Check out our enviable performance in both bull and bear markets.

Read More »

UPDATE ON FLEXION THERAPEUTICS $FLXN $SYN

March 23, 2017

This post was just published on ZYX Buy Change Alert. The stock has surged to over $26 as of this writing. Consider not chasing the price.  If you do not have a fill, we are raising the top end of the buy zone to $24.31 and the preferred point is being raised to $23.36. You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES. Please click here to take advantage of a FREE  30 day trial. Check out our enviable performance in both bull and bear markets.

Read More »

INTELLIGENCE: A NEW IDEA ON FLEXION THERAPEUTICS, RUMORS OF A BUYOUT $FLXN $SNY

March 23, 2017

This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide intelligence on trades that we do not recommend, but our subscribers may be able to take advantage. FLXN is a biopharma. There are reports of a potential buyout buy SNY.  The stock is jumping as we are writing.  This is suitable only for super aggressive investors as the risk of loss

Read More »

THE REAL REASON BEHIND THE GOLD MOVE IS NOT WHAT YOU THINK, EXTRACTING PROFITS TRADE AFTER TRADE $NUGT $GLD $SLV

March 22, 2017

The real reason behind gold move is not what you think.  It is the healthcare bill as I will explain later in this article.  I will also show you how at The Arora Report we are extracting profits trade after trade from precious metals with a real live example of a trade that is in progress as of this writing. In addition to taking very long term positions in precious metals, at The Arora Report we also selectively undertake short-term trades.  Short-term trades are not for everyone, but those who can handle them correctly, profits can be substantial. To fully

Read More »

SIGNAL: 79% – 150% RETURN ON APPLIED MATERIALS, NOW IN THE TARGET ZONE, TAKE PARTIAL PROFITS, RAISING THE TARGET, % DIP TO BUY IF NOT HOLDING $AMAT

March 21, 2017

This post was just published on ZYX Buy Change Alert. AMAT makes semiconductor manufacturing equipment.  This has been one of the strongest stocks in Trump rally.  AMAT is also in the Model Portfolio.  Depending upon when and how you bought AMAT, you are looking at 79% to 150% return in about a year or less.  Of course those who bought recently would have a lower return. Our target has been $38 to $41.  The stock jumped up to close at $39.60.  We are raising the target zone to $48 to $56. Recommended position size has been 30% to 50% of the full

Read More »

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

AI is power hungry. Investors will make a fortune from nuclear power for AI.

Get the list of 12 nuclear power stocks to grab your share of the profits.

Big Tech is investing billions

Making A Fortune
In Nuclear Energy

Golden Age of Nuclear Energy

Skip to content